Safety of Pill-in-the-Pocket Class 1C Antiarrhythmic Drugs for Atrial Fibrillation

Safety of Pill-in-the-Pocket Class 1C Antiarrhythmic Drugs for Atrial Fibrillation - JCEP December 2022

Our data support the current recommendation to initiate pill-in-the-pocket (PIP) antiarrhythmic drugs (AAD) in a monitored setting because of rare significant adverse reactions that can require urgent intervention.

Editor-in-Chief

Kalyanam Shivkumar, MD, PhD, FACC

CME Editor
Kenneth A. Ellenbogen, MD, FACC

Author
Mahmoud Houmsse, MD, FACC

Important Dates
Date of Release: December 19, 2022
Term of Approval/Date of CME/MOC Expiration: December 18, 2023

Summary


Availability:	Retired


Cost:	FREE


Credit Offered:	No Credit Offered